HAVANA, Cuba, Sep 26 (ACN) On the morning of this Wednesday, the Biotechnology and Pharmaceutical Industries Group Biocubafarma announced that the first Cuban-American biotechnology company has been created: Innovative Immunotherapy Alliance SA, which will be based in the Special Zone of Development Mariel.
This new joint venture has been created among the commercial subsidiaries of two renowned research centers: the Molecular Immunology Center of Cuba and the Roswell Park Comprehensive Cancer Center of the United States.
This historic step in the scientific collaboration between the two countries will allow the advancement of the research and development of new anti-cancer drugs, which can prolong and improve the survival of thousands of patients in the United States.
The new biotechnology company will include among its products the drug CIMAVax-EGF, known therapy against lung cancer, and three additional treatments of immunotherapy for different tumors, all developed in Cuba.
In the first years, the company will have as main objective to develop scientific and clinical research to demonstrate the safety and effectiveness of these novel treatments in the United States.
If these studies are successful, the company will be in a position to export these products for the benefit of American patients, once the necessary approvals have been obtained by the regulatory agency for medicines in the country
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio